Literature DB >> 29392976

Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction.

Aldo E Calogero1, Giovanni Burgio1, Rosita A Condorelli1, Rossella Cannarella1, Sandro La Vignera1.   

Abstract

Benign prostatic hyperplasia (BPH) is very common in aging men and causes lower urinary tract symptoms (LUTS), which decrease health-related quality of life. A number of evidence suggests that other than ageing, modifiable factors, such as increasing prostate volume, obesity, diet, dyslipidemia, hormonal imbalance, hypertension, metabolic syndrome, alcohol, and smoking, also contribute to the development of BPH and/or LUTS. More recently, erectile dysfunction (ED) has been linked to LUTS/BPH as a part of this syndrome, suggesting that patients with BPH or LUTS easily develop ED, and that LUTS/BPH symptoms often coexist with ED. This article focuses on the epidemiology and risk factors of the combined phenotype LUTS/BPH - ED.

Entities:  

Keywords:  Erectile dysfunction; LUTS; prostatic hyperplasia

Mesh:

Year:  2018        PMID: 29392976     DOI: 10.1080/13685538.2018.1434772

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  24 in total

1.  Arterial erectile dysfunction is an early sign of vascular damage: the importance for the prevention of cardiovascular health.

Authors:  Sandro La Vignera; Rosita A Condorelli; Rossella Cannarella; Filippo Giacone; Aldo E Calogero
Journal:  Ann Transl Med       Date:  2019-07

Review 2.  Impact of Immune System Activation and Vascular Impairment on Male and Female Sexual Dysfunction.

Authors:  Fabiano B Calmasini; Nicole Klee; R Clinton Webb; Fernanda Priviero
Journal:  Sex Med Rev       Date:  2019-07-17

3.  Benign prostatic hyperplasia and cardiovascular risk: a prospective study among Chinese men.

Authors:  Xiaowen Wang; Yang Su; Chao Yang; Yonghua Hu; Jia-Yi Dong
Journal:  World J Urol       Date:  2021-08-23       Impact factor: 4.226

4.  Radial Extracorporeal Shock Wave Therapy as a Novel Agent for Benign Prostatic Hyperplasia Refractory to Current Medical Therapy.

Authors:  Dai Zhang; Yun-Lei Wang; Da-Xin Gong; Zhao-Xuan Zhang; Xiao-Tong Yu; Yue-Wen Ma
Journal:  Am J Mens Health       Date:  2019 Jan-Feb

5.  Association between lower urinary tract symptoms and cigarette smoking or alcohol drinking.

Authors:  Jin-Won Noh; Ki-Bong Yoo; Kyoung-Beom Kim; Jae Heon Kim; Young Dae Kwon
Journal:  Transl Androl Urol       Date:  2020-04

Review 6.  Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia.

Authors:  Zhao-Jun Yu; Hai-Lan Yan; Fang-Hua Xu; Hai-Chao Chao; Lei-Hong Deng; Xiang-Da Xu; Jian-Biao Huang; Tao Zeng
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

Review 7.  The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective.

Authors:  Teow J Phua
Journal:  Medicines (Basel)       Date:  2021-06-11

8.  Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.

Authors:  Deli Liu; Jonathan E Shoag; Daniel Poliak; Ramy S Goueli; Vaishali Ravikumar; David Redmond; Aram Vosoughi; Jacqueline Fontugne; Heng Pan; Daniel Lee; Domonique Thomas; Keyan Salari; Zongwei Wang; Alessandro Romanel; Alexis Te; Richard Lee; Bilal Chughtai; Aria F Olumi; Juan Miguel Mosquera; Francesca Demichelis; Olivier Elemento; Mark A Rubin; Andrea Sboner; Christopher E Barbieri
Journal:  Nat Commun       Date:  2020-04-24       Impact factor: 14.919

9.  The impact of smoking on male lower urinary tract symptoms (LUTS).

Authors:  Takashi Kawahara; Hiroki Ito; Hiroji Uemura
Journal:  Sci Rep       Date:  2020-11-19       Impact factor: 4.379

10.  Periprostatic fat thickness measured on MRI correlates with lower urinary tract symptoms, erectile function, and benign prostatic hyperplasia progression.

Authors:  Bo Zhang; Xiang Chen; Yu-Hang Liu; Yu Gan; Pei-Hua Liu; Zhi Chen; Wei-Ping Xia; Guo-Yu Dai; Feng Ru; Ze-Xiang Jiang; Yao He
Journal:  Asian J Androl       Date:  2021 Jan-Feb       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.